ABT
Abbott Laboratories
ABT's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over ABT overall, supported by stronger modeled upside and stronger fundamentals.
ABT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Healthy | |
| Under pressure |
ABT's revenue and cash flow are currently healthy, and its profitability is stable, but its balance sheet is under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ABT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $107 | — |
| Cheap | 22x | $58.67 | -45% |
| Fair | 33x | $88.57 | -17% |
| Current | 40x | $107 | — |
| Expensive | 45x | $121 | +13% |
Historical ranges are pointers, not guarantees.
ABT has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ABT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Moderate | |
| High |
Analysts expect earnings and revenue growth for ABT, with profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over ABT on the outlook, with more favorable profitability expectations.
ABT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.84 | +118% |
| Q3 2026 | $2.68 | -66% |
| Q2 2026 | $3.09 | -61% |
| Q1 2026 | $3.57 | -54% |
| Q4 2025 | $3.72 | -51% |
| Q3 2025 | $7.97 | +142% |
| Q2 2025 | $7.97 | +151% |
| Q1 2025 | $7.70 | +140% |
| Q4 2024 | $7.64 | +134% |
ABT's earnings per share have fallen from their peak: $2.68 over the past year, against $7.97 in mid-2025.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ABT on earnings, with more consistent year-over-year improvement.
ABT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $13B | +14% |
| Q2 2026 | $12.6B | +13% |
| Q1 2026 | $11.2B | +7.8% |
| Q4 2025 | $11.5B | +4.4% |
| Q3 2025 | $11.4B | +6.9% |
| Q2 2025 | $11.1B | +7.4% |
| Q1 2025 | $10.4B | +4% |
| Q4 2024 | $11B | +7.2% |
ABT's revenue has grown year over year for 12 quarters in a row: $13B last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | -7.7 points |
| Q2 2026 | 13% | -5 points |
| Q1 2026 | 12% | -4.3 points |
| Q4 2025 | 20% | +2.2 points |
| Q3 2025 | 18% | +0.6 points |
| Q2 2025 | 18% | +2.3 points |
| Q1 2025 | 16% | +2.4 points |
| Q4 2024 | 17% | 0 points |
ABT's operating margin was 10% last quarter, down 7.7 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ABT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ABT on profitability, with a higher operating margin.
ABT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2B | -47% |
| Q2 2026 | $2B | +29% |
| Q1 2026 | $916M | -1.8% |
| Q4 2025 | $2.6B | +22% |
| Q3 2025 | $2.3B | +6.6% |
| Q2 2025 | $1.5B | +8.3% |
| Q1 2025 | $933M | +49% |
| Q4 2024 | $2.1B | -5.9% |
ABT's free cash flow has been positive every quarter for seven years: $6.8B over the past year, down 2.3% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ABT on cash flow, with more consistent year-over-year improvement.
ABT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -5.1M shares |
| 1 year | -0.7% | -11.5M shares |
| 3 years | -0.6% | -10.4M shares |
| 5 years | -2.9% | -51.1M shares |
| Available history | -2.4% | -43.1M shares |
ABT has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $11M |
| Q2 2026 | $1B |
| Q1 2026 | $180M |
| Q4 2025 | $302M |
| Q3 2025 | $305M |
| Q2 2025 | $6M |
| Q1 2025 | $280M |
| Q4 2024 | $315M |
ABT spent $1.5B buying back its own shares over the past year, up 70% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ABT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.6x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.6x | Very low |
| Q1 2025 | 0.7x | Very low |
| Q4 2024 | 0.7x | Very low |
ABT's net debt is about 2.6 years of its operating earnings (EBITDA), up from less than a year a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over ABT on leverage, with a lower net debt burden relative to earnings.
ABT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.0 | Neutral |
| Stochastic | 57.1 | Neutral |
ABT's weekly RSI is 54 (neutral) and its Stochastic is 57 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ABT PE vs Healthcare Sector
| Metric | ABT | Sector median | Relative |
|---|---|---|---|
| PE | 40x | 26x | 55% above |
| PE % | 81 | 29 | 52 pts above |
ABT has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ABT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $103.8 | 3.3% above |
| 20 week MA | $104.5 | 2.6% above |
| 50 week MA | $104.9 | 2.3% above |
| 100 week MA | $117.0 | 8.4% below |
| 200 week MA | $112.4 | 4.6% below |
ABT has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 4.6% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ABT on trend strength, trading above more of its moving averages.
ABT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $87.4 | $108.4 | +24% |
| 2021 | $108.4 | $139.2 | +28% |
| 2022 | $139.2 | $108.2 | -22% |
| 2023 | $108.2 | $110.1 | +1.7% |
| 2024 | $110.1 | $115.0 | +4.5% |
| 2025 | $115.0 | $124.8 | +8.6% |
| 2026 YTD | $124.8 | $107.3 | -14% |
ABT has finished higher in five of the last six years. It's down 14% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ABT on returns for 2026, with the stronger performance.